A novel method for simultaneously visualizing beneft and risk over time is presented. The underlying model represents a subject’s beneft-risk state at a given time as one of fve discrete clinical states, one being premature study withdrawal. The new graphic uses colors to represent each subject’s changing state over the course of the clinical trial. The user can quickly grasp how a treatment affects subjects in aggregate, then further examine how individuals are affected. It is possible to tell whether the benefcial and harmful outcomes are correlated. The method is particularly appropriate for treatments that provide only symptomatic relief. An approved drug for chronic pain is presented as a worked example.
This is a preview of subscription content, log in to check access.
Buy single article
Instant unlimited access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
O’Neill RT. A perspective on characterizing benefts and risks derived from clinical trials: can we do more? Drug Inf J. 2008;42:235–245.
National Research Council. The Prevention and Treatment of Missing Data in Clinical Trials. Panel on Handling Missing Data in Clinical Trials. Committee on National Statistics, Division of Behavioral and Social Sciences and Education. Washington, DC: National Academies Press; 2010.
Rubin DB. Estimating causal effects of treatments in randomized and nonrandomized studies. J Educ Psychol. 1974;66:688–701.
Rubin DB. Causal inference using potential outcomes: design, modeling, decisions. J Am Stat As-soc. 2005;100:322–331.
Chuang-Stein C, Mohberg NR, Sinkula MS. Three measures for simultaneously evaluating benefts and risks using categorical data from clinical trials. Stat Med. 1991;10:1349–1359.
Chuang-Stein C. A new proposal for beneft-less-risk analysis in clinical trials. Control Clin Trials. 1994;15:30–43.
Szarfman A, Talarico L, Levine JG. Analysis and risk assessment of hematological data from clinical trials. In IG Sipes, CA Mcqueen, AJ Gandolf, eds. Comprehensive Toxicology 4. Amsterdam: Elsevier Science; 1997.
Tufte ER. The Visual Display of Quantitative Information. Cheshire, CT: Graphics Press; 1983.
Ceesay P, Entsuah R. Beneft risk assessment incorporating time component. Paper presented at Joint Statistical Meetings, August 4, 2010, Vancouver.
Norton JD. A longitudinal model for medical beneft-risk analysis, with case study. Paper presented at International Chinese Statistical Association 2010 Applied Statistics Symposium, June 21, 2010, Indianapolis.
Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149–158.
Mantel N. Chi-square tests with one degree of freedom; extensions of the Mantel-Haenszel procedure. J Am Stat Assoc. 1963;58:690–700.
Gould AL. A new approach to the analysis of clinical drug trials with withdrawals. Biometrics. 1980;36(4):721–727.
The authors report no relevant relationships to disclose
About this article
Cite this article
Norton, J.D. A Longitudinal Model and Graphic for Beneft-risk Analysis, With Case Study. Ther Innov Regul Sci 45, 741–747 (2011) doi:10.1177/009286151104500510
- Missing data